| Keywords: |
treatment outcome; clinical trial; constipation; drowsiness; placebo; drug efficacy; drug potentiation; drug safety; hypertension; side effect; research design; evidence based medicine; evidence-based medicine; unindexed drug; drug eruption; chlorpromazine; delirium; inflammation; dose-response relationship, drug; dizziness; flushing; confusion; drug research; drug mechanism; phenobarbital; randomized controlled trials; systematic review; alcohol; xerostomia; short survey; safety; phytotherapy; plant extracts; motion sickness; headache; drug absorption; drug half life; myoclonus; somnolence; coma; psychosis; drug dose regimen; dry skin; drug contraindication; hallucination; urine retention; tremor; hyperreflexia; visual impairment; photophobia; meta analysis; autonomic neuropathy; tachycardia; radiation dermatitis; urticaria; atropine; antiarrhythmic agent; muscle cramp; agitation; menopausal syndrome; tricyclic antidepressant agent; drug indication; airway obstruction; abdominal distension; drug elimination; diphenhydramine; homeopathy; plants, medicinal; vertigo; otitis media; teratogenicity; irritable colon; contact dermatitis; ergot alkaloid; amitriptyline; hyposalivation; muscle rigidity; amantadine; peptic ulcer; multicenter studies; clozapine; sweat gland disease; scopolamine butyl bromide; propranolol; drug intoxication; cisapride; mydriasis; tachypnea; benzatropine; muscle hypertonia; amobarbital; convulsion; physostigmine; bethanechol; biperiden; brompheniramine; carbinoxamine; heart ventricle extrasystole; humans; human; priority journal; slurred speech; acetophenazine; ambenonium; b and o supprettes; bel phen ergot s; belladonna alkaloid; bellergal; bellergal s; bellergil; cafergot; clemastine; cyclopentolate; distovagal; ergotamine tartrate; phenerbel s; pms opium and beladonna; tacrine; drug alcohol interaction; premenstrual syndrome; atropa belladonna; belladonna alkaloids; plants, toxic
|
